DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Public ClinicalTrials.gov record NCT06075953. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Study identification
- NCT ID
- NCT06075953
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Tamoxifen Drug
- Exemestane Drug
- Letrozole Drug
- Anastrazole Drug
- Testosterone + Anastrazole Drug
- Elacestrant Drug
- Z-endoxifen Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 16, 2024
- Primary completion
- Oct 31, 2028
- Completion
- Oct 31, 2033
- Last update posted
- Jul 20, 2026
2024 – 2033
United States locations
- U.S. sites
- 28
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Berkeley Outpatient Center | Berkeley | California | 94158 | Recruiting |
| City of Hope -Duarte Cancer Center | Duarte | California | 91010 | Recruiting |
| City of Hope - Lennar Foundation Cancer Center | Irvine | California | 92618 | Recruiting |
| UCLA | Los Angeles | California | 90095 | Recruiting |
| UCSF | San Francisco | California | 94158 | Recruiting |
| City of Hope | South Pasadena | California | 91030 | Recruiting |
| John Muir Health | Walnut Creek | California | 94598 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | Recruiting |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| Maple Grove Cancer Center | Maple Grove | Minnesota | 55369 | Recruiting |
| Hennepin Healthcare -Minneapolis | Minneapolis | Minnesota | 55404 | Recruiting |
| University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| Health Partners - Frauenshuh Cancer Center | Saint Louis Park | Minnesota | 55426 | Recruiting |
| Health Partners - Regions Hospital | Saint Paul | Minnesota | 55101 | Recruiting |
| Englewood Hospital and Medical Center | Englewood | New Jersey | 07631 | Recruiting |
| Mount Sinai Union Square | New York | New York | 10003 | Recruiting |
| Mount Sinai Chelsea | New York | New York | 10011 | Recruiting |
| Mount Sinai West | New York | New York | 10019 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Recruiting |
| Duke Cancer Institute | Durham | North Carolina | 27710 | Recruiting |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | Recruiting |
| Bryn Mawr Hospital | Bryn Mawr | Pennsylvania | 19010 | Active, not recruiting |
| Paoli Hospital | Paoli | Pennsylvania | 19301 | Active, not recruiting |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | Active, not recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06075953, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06075953 live on ClinicalTrials.gov.